Cargando…

Case Report: Successful Immunotherapy Improved the Prognosis of the Unfavorable Subset of Cancer of Unknown Primary

BACKGROUND: Cancer of unknown primary (CUP) is heterogeneous and has a wide variety of clinical presentations and a poor prognosis in most patients, with a median overall survival of only 6 months. The development of molecular profiling contributes to precision therapy, and targeted drugs and immune...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mei, Jie, Wang, Hao, Fan, Honghong, Ding, Junli, Xu, Junying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256999/ https://www.ncbi.nlm.nih.gov/pubmed/35812375 http://dx.doi.org/10.3389/fimmu.2022.900119

Ejemplares similares

Durable response of chemotherapy for cancer of unknown primary with unfavorable subset developed in retroperitoneal space
por: Matsukawa, Atsuki, et al.
Publicado: (2021)

Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site
por: Kodaira, Makoto, et al.
Publicado: (2018)

Diagnostic value of tumor markers in identifying favorable or unfavorable subsets in patients with cancer of unknown primary: a retrospective study
por: Takamizawa, Shigemasa, et al.
Publicado: (2022)

Microfluidic devices: The application in TME modeling and the potential in immunotherapy optimization
por: Li, Yuting, et al.
Publicado: (2022)

Total T Cell Density and Expression of T Memory Stem Cell Markers are Associated with Better Prognosis in Colon Cancer
por: Ding, Junli, et al.
Publicado: (2023)

Treatable Subsets in Cancer of Unknown Primary Origin
por: Sumi, Hajime, et al.
Publicado: (2001)

Elevated MPP6 expression correlates with an unfavorable prognosis, angiogenesis and immune evasion in hepatocellular carcinoma
por: Cheng, Qianqian, et al.
Publicado: (2023)

Interaction Between Macrophage Extracellular Traps and Colon Cancer Cells Promotes Colon Cancer Invasion and Correlates With Unfavorable Prognosis
por: Chen, Tianli, et al.
Publicado: (2021)

Editorial: The Spectrum of Lymphoid Subsets in Allergic Diseases: Immune Regulation and Immunotherapy
por: Liu, Zheng, et al.
Publicado: (2022)

Longitudinal analysis of DC subsets in patients with ovarian cancer: Implications for immunotherapy
por: Mastelic-Gavillet, Beatris, et al.
Publicado: (2023)

Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy
por: Kersten, Kelly, et al.
Publicado: (2015)

A generational comparison for unfavorable cancer of unknown primary in a single institute over 20 years
por: Tang, Cheng‐Yu, et al.
Publicado: (2022)

Immunotherapy improves disease prognosis by affecting the tumor microenvironment: A bibliometric study
por: Wu, Xin, et al.
Publicado: (2022)

HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma
por: Huang, Fu-xue, et al.
Publicado: (2022)

Predicting Success of Allergen-Specific Immunotherapy
por: Zissler, Ulrich M., et al.
Publicado: (2020)

Pembrolizumab plus platinum-based chemotherapy for unfavorable cancer of unknown primary site: Case report
por: Kamada, Teppei, et al.
Publicado: (2020)

Co-Mutation of FAT3 and LRP1B in Lung Adenocarcinoma Defines a Unique Subset Correlated With the Efficacy of Immunotherapy
por: Zhu, Mingyu, et al.
Publicado: (2022)

Tertiary lymphoid structures predict the prognosis and immunotherapy response of cholangiocarcinoma
por: Shang, Taiyu, et al.
Publicado: (2023)

Unfavorable prognosis of nephroblastoma in adults
por: Huszno, Joanna, et al.
Publicado: (2013)

Combined Immunotherapy in Metastatic Melanoma with Unknown Primary
por: Khan, Yasir, et al.
Publicado: (2019)

Current State of Dendritic Cell-Based Immunotherapy: Opportunities for in vitro Antigen Loading of Different DC Subsets?
por: Huber, Anne, et al.
Publicado: (2018)

GBP5 Identifies Immuno-Hot Tumors and Predicts the Therapeutic Response to Immunotherapy in NSCLC
por: Fan, Honghong, et al.
Publicado: (2023)

Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma
por: Zeng, Weibiao, et al.
Publicado: (2023)

Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma
por: Sadozai, Hassan, et al.
Publicado: (2017)

Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy
por: Shaver, Kari A., et al.
Publicado: (2021)

Defining a Distinct Immunotherapy Eligible Subset of Patients with Cancer of Unknown Primary Using Gene Expression Profiling with the 92‐Gene Assay
por: Raghav, Kanwal, et al.
Publicado: (2020)

Evaluation of prognostic factors and the role of chemotherapy in unfavorable carcinoma of unknown primary site: a 10-year cohort study
por: Chen, Kuo-Wei, et al.
Publicado: (2012)

Using a Gene Network of Pyroptosis to Quantify the Responses to Immunotherapy and Prognosis for Neuroblastoma Patients
por: Luo, Bingying, et al.
Publicado: (2022)

SIRGs score may be a predictor of prognosis and immunotherapy response for esophagogastric junction adenocarcinoma
por: OuYang, Li-Ying, et al.
Publicado: (2022)

Comprehensive analysis of the prognosis, tumor microenvironment, and immunotherapy response of SDHs in colon adenocarcinoma
por: Nan, Han, et al.
Publicado: (2023)

The relevance between hypoxia-dependent spatial transcriptomics and the prognosis and efficacy of immunotherapy in claudin-low breast cancer
por: Sun, Huizhi, et al.
Publicado: (2023)

Pyroptosis-Related Signature Predicts Prognosis and Immunotherapy Efficacy in Muscle-Invasive Bladder Cancer
por: Zhang, Qi, et al.
Publicado: (2022)

Intratumoral neutrophil extracellular traps are associated with unfavorable clinical outcomes and immunogenic context in pancreatic ductal adenocarcinoma
por: Chen, Xianlong, et al.
Publicado: (2022)

Multi-omics analysis reveals the association between elevated KIF18B expression and unfavorable prognosis, immune evasion, and regulatory T cell activation in nasopharyngeal carcinoma
por: Tang, Siqi, et al.
Publicado: (2023)

DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma
por: Chen, Yunfei, et al.
Publicado: (2021)

Immunoregulatory Monocyte Subset Promotes Metastasis Associated With Therapeutic Intervention for Primary Tumor
por: Shibuya, Takumi, et al.
Publicado: (2021)

Comprehensive Analysis of the Tumor Immune Microenvironment Landscape in Glioblastoma Reveals Tumor Heterogeneity and Implications for Prognosis and Immunotherapy
por: Zhao, Rongrong, et al.
Publicado: (2022)

ncRNAs-mediated overexpression of STIL predict unfavorable prognosis and correlated with the efficacy of immunotherapy of hepatocellular carcinoma
por: Xu, Longwen, et al.
Publicado: (2023)

Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets
por: Wimmers, Florian, et al.
Publicado: (2014)

The Comprehensive Analysis Identified an Autophagy Signature for the Prognosis and the Immunotherapy Efficiency Prediction in Lung Adenocarcinoma
por: Li, Xizhe, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_va2l70f4jvaei3841vuiv7rdr4